Befotertinib
EGFR Sensitive Mutation
Betta Pharmaceuticals Co., Ltd.Phase 3Active
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the EGFR Sensitive Mutation cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Catequentinib Degan Lu | Phase 3 | B |
Penpulimab Degan Lu | Phase 3 | B |
Same molecule, other indications
Befotertinib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →